Literature DB >> 26064343

Effect of combined application insulin and insulin detemir on continous glucose monitor in children with type 1 diabetes mellitus.

Xiao-Yun Chen1, Qing Dong1, Gui-Mei Li2.   

Abstract

Insulin detemir is a soluble long-acting human insulin analogue at neutral pH with a unique mechanism of action, which could strengthen the effects of insulin. This study aims to explore the effects of insulin combined with insulin detemir on the continous glucose in children with type 1 diabetes mellitus. In this study, 150 patients with type 1 diabetes enrolled were included and randomly divided into 3 groups: insulin group (group A), insulin detemir group (group B) and insulin combined with insulin detemir group (group C). Each subject underwent 72 h of continuous glucose monitoring (CGM). MAGE, HbA1c and Noctumal Hypoglycemia levels were examined by using the ELISA kits. The body weight changes were also detected in this study. The results indicated that the information including age, body weight, disease duration and glucose level and HbA1c percentage on the start time point among three groups indicated no statistical differences. Insulin combined with insulin detemir decrease MAGE and HbA1c level in Group C compared to Group A and Group A (P < 0.05). Insulin combined with insulin detemir decreas noctumal hypoglycemia levels and body weight changes (P < 0.05). In conclusion, this study confirmed efficacy of insulin detemir by demonstrating non-inferiority of insulin detemir compared with insulin with respect to HbA1c, with an improved safety profile including significantly fewer hypoglycaemic episodes and less undesirable weight gain in children.

Entities:  

Keywords:  Diabetes mellitus; hypoglycemia; insulin detemir; insulin therapy

Year:  2015        PMID: 26064343      PMCID: PMC4443177     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  12 in total

1.  Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans.

Authors:  G A Brunner; G Sendhofer; A Wutte; M Ellmerer; B Søgaard; A Siebenhofer; S Hirschberger; G J Krejs; T R Pieber
Journal:  Exp Clin Endocrinol Diabetes       Date:  2000       Impact factor: 2.949

2.  Evaluation of mean platelet volume in patients with type 2 diabetes mellitus and blood glucose regulation: a marker for atherosclerosis?

Authors:  Kemal Turker Ulutas; Recep Dokuyucu; Fatih Sefil; Erhan Yengil; Ahmet Taner Sumbul; Hatice Rizaoglu; Ihsan Ustun; Erkan Yula; Tevfik Sabuncu; Cumali Gokce
Journal:  Int J Clin Exp Med       Date:  2014-04-15

3.  Analysis for hypertension and related risk factors of physical examination population.

Authors:  Sen Qiao; Qing Ye; Yue Dou; Mingzi Li; Yuhong Kou; Dawei Qian; Mingcheng Li; Gang Wang
Journal:  Int J Clin Exp Med       Date:  2013-09-25

4.  Weight change upon once-daily initiation of insulin detemir with or without dietary intervention in overweight or obese insulin-naïve individuals with type 2 diabetes: results from the DIET trial.

Authors:  K Niswender; M Piletic; H Andersen; L Conradsen Hiort; P Hollander
Journal:  Diabetes Obes Metab       Date:  2013-10-29       Impact factor: 6.577

5.  The importance of HbA1c and glucose variability in patients with type 1 and type 2 diabetes: outcome of continuous glucose monitoring (CGM).

Authors:  Giovanni Sartore; Nino Cristiano Chilelli; Silvia Burlina; Paola Di Stefano; Francesco Piarulli; Domenico Fedele; Andrea Mosca; Annunziata Lapolla
Journal:  Acta Diabetol       Date:  2012-04-01       Impact factor: 4.280

6.  Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.

Authors:  K Hermansen; S Madsbad; H Perrild; A Kristensen; M Axelsen
Journal:  Diabetes Care       Date:  2001-02       Impact factor: 19.112

7.  Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.

Authors:  P Kurtzhals; L Schäffer; A Sørensen; C Kristensen; I Jonassen; C Schmid; T Trüb
Journal:  Diabetes       Date:  2000-06       Impact factor: 9.461

Review 8.  New insulins in the treatment of diabetes mellitus.

Authors:  Anders Lindholm
Journal:  Best Pract Res Clin Gastroenterol       Date:  2002-06       Impact factor: 3.043

9.  Calculation of HbA1c and glycated albumin from serially measured self-monitored blood glucose in patients with type 1 diabetes mellitus.

Authors:  Masafumi Koga; Shigeru Suzuki; Kumihiro Matsuo; Yusuke Tanahashi; Hiroshi Azuma; Soji Kasayama
Journal:  Clin Chim Acta       Date:  2013-08-06       Impact factor: 3.786

10.  Insulin analogues in children with Type 1 diabetes: a 52-week randomized clinical trial.

Authors:  N Thalange; A Bereket; J Larsen; L C Hiort; V Peterkova
Journal:  Diabet Med       Date:  2013-02       Impact factor: 4.359

View more
  1 in total

1.  Technological Ecological Momentary Assessment Tools to Study Type 1 Diabetes in Youth: Viewpoint of Methodologies.

Authors:  Mary Katherine Ray; Alana McMichael; Maria Rivera-Santana; Jacob Noel; Tamara Hershey
Journal:  JMIR Diabetes       Date:  2021-06-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.